Coherus Oncology, Inc.
CHRS
$1.13
-$0.04-3.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.41% | 229.25% | -40.84% | -5.09% | -82.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.41% | 229.25% | -40.84% | -5.09% | -82.46% |
| Cost of Revenue | 87.67% | 84.36% | -59.96% | -36.58% | -92.72% |
| Gross Profit | -19.18% | 469.16% | 191.59% | 19.51% | -74.94% |
| SG&A Expenses | -5.36% | -12.17% | -27.31% | -23.85% | -39.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.65% | -10.86% | -42.11% | -25.79% | -46.47% |
| Operating Income | -14.79% | 20.55% | 43.94% | 78.28% | -14.71% |
| Income Before Tax | 18.21% | 30.33% | 36.35% | 73.14% | -27.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.21% | 30.33% | 36.35% | 72.88% | -27.95% |
| Earnings from Discontinued Operations | 717.15% | -105.37% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2,404.52% | -154.99% | 36.35% | 72.88% | 69.86% |
| EBIT | -14.79% | 20.55% | 43.94% | 78.28% | -14.71% |
| EBITDA | -15.69% | 20.28% | 44.64% | 83.03% | -14.19% |
| EPS Basic | 2,380.18% | -153.52% | 38.52% | 77.00% | 77.10% |
| Normalized Basic EPS | -5.13% | 19.69% | -187.35% | 75.64% | 25.15% |
| EPS Diluted | 2,380.18% | -153.52% | 34.87% | 77.24% | 77.10% |
| Normalized Diluted EPS | -5.13% | 19.69% | -187.35% | 75.64% | 25.15% |
| Average Basic Shares Outstanding | 1.10% | 2.76% | 3.52% | 17.88% | 31.57% |
| Average Diluted Shares Outstanding | 1.10% | 2.76% | 3.52% | 17.88% | 31.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |